Prostate Biopsy Articles & Analysis
-
Bio-Techne`s Exosome Diagnostics Laboratory Announces CE-IVD Certification for Exodx Prostate Test
Bio-Techne Corporation (NASDAQ:TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has completed its clinical validation of an in vitro diagnostic (IVD) version of the ExoDx™ Prostate test (EPI) kit enabling self-certification as CE-IVD as of March 22, 2021. Bio-Techne Corporation (NASDAQ:TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has ...
-
Cleveland Diagnostics Announces Publication of Real-World Study Demonstrating the Clinical Utility of IsoPSA for Prostate Cancer Risk Assessment
Cleveland Diagnostics, Inc., a clinical-stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, announced today the publication of a large real-world clinical utility study in Urology Practice, a peer-reviewed journal of the American Urological Association. The study, led by Dr. Eric Klein, Emeritus Professor and Chair of the Glickman Urological ...
-
Cleveland Diagnostics Announces Inclusion of IsoPSA in National Comprehensive Cancer Network Guidelines for Prostate Cancer Early Detection
Cleveland Diagnostics, Inc., a clinical-stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, announced today that its prostate cancer test, IsoPSA, has been added to the National Comprehensive Cancer Network (NCCN) Guidelines for Prostate Cancer Early Detection (version 1.2022). The NCCN panel now recommends the use of IsoPSA as an option to ...
-
Cleveland Diagnostics Announces Publication of Multicenter IsoPSA Clinical Validation Study Demonstrating Improved Accuracy Over Prostate-Specific Antigen Test
Cleveland Diagnostics, Inc., a clinical-stage company focused on developing next-generation diagnostic tests for the detection of cancers, today announced the online publication of results from a multicenter validation study of IsoPSA™, a novel structure-based prostate cancer assay, in Journal of Urology. The study validated the findings from a preliminary study published earlier in ...
-
Bio-Techne and Hall of Famer Cal Ripken Jr -Announce Partnership to Raise Awareness and Education to Empower Men With Prostate Cancer
Bio-Techne Corporation (NASDAQ:TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has established a new partnership with Hall of Famer and baseball's all-time "Iron Man", Cal Ripken Jr. This year marks 25 years since Ripken played in his 2,131st consecutive game, eclipsing the thought to be unbreakable record of 2,130 set by the legendary Lou Gehrig. Recently the 21-year Major ...
-
Cleveland Diagnostics Announces Preliminary Results from Multicenter IsoPSA Study Demonstrating Significantly Improved Accuracy Over Standard Prostate-Specific Antigen (PSA) Test
Cleveland Diagnostics, Inc., a biotechnology company focused on developing next-generation diagnostics for the detection of cancers, today announced the online publication of interim results for an ongoing multi-center trial of the IsoPSA™ prostate cancer test in European Urology. The findings illustrate a significantly improved diagnostic accuracy over the current gold standard, ...
-
Publication of a Health Economic Analysis Demonstrates IsoPSA Significantly Reduces Unnecessary Prostate Cancer Biopsies and Costs
Cleveland Diagnostics, Inc., a clinical-stage biotechnology company focused on the development of next-generation diagnostic tests for early detection of cancers, announced today the publication of a health economic analysis in Urology Practice. The publication demonstrates the cost effectiveness and economic utility of Cleveland Diagnostics’ IsoPSA test for the detection of clinically ...
-
New Studies Examine the Use of ExactVu Micro-Ultrasound to Improve on Prostate MRI
Clinical evidence for micro-ultrasound is growing exponentially with publications from more than a dozen institutions reporting on more than 3,000 individual biopsy cases. Toronto, Canada -- (March 31, 2021) Exact Imaging™ (www.exactimaging.com), the world’s leader in high-resolution micro-ultrasound systems enabling real-time imaging and biopsy guidance for the prostate, and its ...
-
Detecting the previously undetectable
Combining engineering and medicine can lead to world-leading tools like the Raman spectroscopy, which can help to distinguish cancer cells from healthy cells; for example, in brain tumour surgery.ISTOCKPHOTO / GETTY IMAGES One of the biggest challenges in brain tumour surgery is making sure that all cancer cells are removed. “If you leave a few cancer cells behind, the cancer will come ...
-
miR Scientific Presents Groundbreaking Data on the Exceptional Accuracy of its Prostate Cancer Liquid-Biopsy Test
NEW YORK, Sept. 20, 2021 /PRNewswire/ -- Data presented from a cross-validation study at the American Urological Association's (AUA) 2021 Annual Meeting confirms that the miR Sentinel® Prostate Cancer Test can detect and risk-classify prostate cancer at the molecular level with predictive accuracy of over 90%, based on a single urine sample. This validation study follows and confirms the ...
-
miR Scientific and Puerto Rico Government team up for Prostate Cancer Prevention Day, to battle the number one cause of cancer-related death among men in the island
NEW YORK and SAN JUAN, Puerto Rico, Sept. 1, 2021 /PRNewswire/ -- miR Scientific, LLC, a healthcare company focused on transforming global cancer management, the Governor of Puerto Rico, Pedro Pierluisi, and the Puerto Rico Health Insurance Administration ("ASES") join forces today to officially make September 1 "Prostate Cancer Prevention Day". This urgent awareness team effort occurs while the ...
-
miR Scientific and Leonie Hill Capital Announce Collaboration to Introduce Breakthrough Urine Liquid Biopsy Prostate Cancer Test in Singapore
High demand seen for effective disease management platform for second most common cancer in Singaporean men NEW YORK and SINGAPORE, March 28, 2022 /PRNewswire/ -- miR Scientific, a New York-based healthcare company dedicated to transforming global cancer management, and Leonie Hill Capital, a Singapore-based organization focused on large-scale, sophisticated healthcare access and distribution, ...
-
miR Scientific to Present the Prostate Cancer Application of its Liquid Biopsy miR Disease Management Platform® at the 12th Annual Prostate Cancer Awareness Day (PCAD) at the Massachusetts State House
NEW YORK, Feb. 25, 2021 /PRNewswire/ -- miR Scientific, LLC, a healthcare company whose purpose is to transform global cancer management by providing early and highly accurate detection, characterization and monitoring of disease, announced today that its Chairman & CEO, Sam Salman, will be virtually presenting at the 12th Annual Prostate Cancer Awareness Day at the Massachusetts State House ...
-
Novosanis launches Colli-Pee containing UAS Large Volumes, offering a new solution for oncology research
Today, Novosanis has launched its novel solution for oncology research applications. Together with our sister company DNA Genotek, we have developed a novel stabilization chemistry, UAS, for the preservation of extracellular vesicle (EV) RNA, and cell-free DNA (cfDNA) in urine, collected with Colli-Pee. Novosanis hereby offers a solution for applications in the field of oncology research and ...
By Novosanis NV
-
I Lost One of the Most Vital Organs - Prostate Cancer Patient Stories
Prostate cancer is the most common type of cancer in men. Every year this diagnosis is made about 900 thousand times, in developed countries the disease affects up to 14% of the entire male population with oncology due to longer life expectancy. We spoke with adult prostate cancer survivors. ...
-
miR Scientific launches "Can do Blue" on September 1, 2022, as Prostate Cancer Awareness Month
NEW YORK and SAN JUAN, Puerto Rico, Aug. 18, 2022 /PRNewswire/ -- miR Scientific, LLC announced the launch of national event #CanDoBlue to create awareness of the need for widespread prostate cancer testing during the 2022 Prostate Cancer Awareness Month (also known as "PCAM"). On September 1, New York, New Jersey, Chicago, and Puerto Rico will simultaneously light up dozens of landmarks and ...
-
miR Scientific is proud to announce the commercial availability of the miR Sentinel™ Prostate Cancer Test
NEW YORK, July 13, 2022 /PRNewswire/ -- miR Scientific, LLC announces the miR Sentinel™ Prostate Cancer Test is now commercially available in the United States, Puerto Rico and select international markets. miR Sentinel™ is a novel, urine-based, molecular test that analyzes small non-coding RNA using a proprietary biostatistical algorithm. The miR Sentinel™ Test assesses the ...
-
Promaxo Announces Sale of In-Office MRI to Arizona State Urological Institute
Promaxo, Inc. (“Promaxo” or the “Company”), a medical imaging, robotics, and AI technology company, announced today the sale of its in-office MRI system to Arizona State Urological Institute (“ASUI”). Promaxo’s single-sided MRI with AI based imaging system, FDA cleared for in-office use, empowers practices and hospitals to accurately and seamlessly guide ...
-
The Ultimate List of Attractive MedTech M&A Targets
Updated May 12, 2021 to reflect 10 new additions, based on recent analyst reports. We’ve also updated the existing companies on the list to reflect recent business developments. From time to time, medtech analysts will call out companies in the private sector that they believe investors should be keeping tabs on. Here is our ultimate list, compiled from analyst reports, of private ...
-
miR Scientific to Present the Prostate Cancer Application of its Liquid Biopsy Disease Management Platform at the 39th Annual J.P. Morgan Healthcare Conference
NEW YORK, Jan. 11, 2021 /PRNewswire/ -- miR Scientific, LLC, a healthcare company whose purpose is to transform global cancer management by providing early and highly accurate detection, characterization and monitoring of disease, announced today that its Chairman & CEO, Sam Salman, will be virtually presenting at the 39th Annual J.P. Morgan Healthcare Conference. Mr. Salman will introduce ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you